Search results
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 8 hours agoNovavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced its submission for an amended Emergency Use...
New COVID-19 strain KP.3 circulating in US. What is the situation in Riverside County?
The Desert Sun via Yahoo News· 42 minutes agoCOVID-19. The CDC recommends the COVID-19 vaccine for anyone 6 months old and older. Recently, ...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA TODAY via Yahoo News· 1 day agoCOVID fall vaccine will target JN.1 The dominant emergence of...vaccine manufacturers Pfizer, Moderna and Novavax ...
COVID shots should target JN.1 variant in fall 2024 campaign, US FDA says
Stars and Stripes· 7 days agoThe U.S. health regulator on Friday advised COVID-19 vaccine manufacturers that new shots for the...
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
CNBC· 5 days agoThe biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rival vaccine ...
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Zacks via Yahoo Finance· 5 days agoModerna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 4 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
There's another COVID variant you should know about: KP.3 now makes up 25% of COVID cases
USA Today· 6 days agoThe Centers for Disease Control and Prevention data shows that a new COVID variant, the KP.3...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoAnd Moderna stock surged more than 9% on Dec. 19, the day it released the news. Moderna also...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 15 hours agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....